Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × Urination × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 4 Neoplasms 2 Lung Neoplasms 2 Disease 2 Colorectal Neoplasms 2 Acute Kidney Injury 2 Urinary Bladder Neoplasms 1 Tuberous Sclerosis 1 Smoldering Multiple Myeloma 1 Salivary Gland Adenoma, Pleomorphic 1 Renal Insufficiency 1 Prostatic Hyperplasia 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms, Plasma Cell 1 Monoclonal Gammopathy of Undetermined Significance 1 Lymphangioleiomyomatosis 1 Liver Cirrhosis 1 Kidney Neoplasms 1 Hematologic Neoplasms 1 Hemangiosarcoma 1 Gallbladder Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Pancreatic Ductal 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1

Interventions

Trastuzumab 556 Paclitaxel 513 Cyclophosphamide 491 Docetaxel 431 Capecitabine 372 Letrozole 336 Fulvestrant 292 Doxorubicin 262 Tamoxifen 245 Carboplatin 243 Anastrozole 211 Radiotherapy 201 exemestane 199 Epirubicin 180 Bevacizumab 178 palbociclib 170 Lapatinib 156 Vinorelbine 155 pertuzumab 152 Gemcitabine 151 pembrolizumab 146 Surveys and Questionnaires 124 Exercise 119 Magnetic Resonance Spectroscopy 117 eribulin 108 Albumin-Bound Paclitaxel 108 Fluorouracil 105 Blood Specimen Collection 103 130-nm albumin-bound paclitaxel 99 Everolimus 94

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03958136 2025-08-17

EPICURE_SEIN

Institut Cancerologie de l'Ouest

Phase NA Active not recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡